title: Sedimentation equilibrium analysis of five lipocortin-related phospholipase A2 inhibitors from human placenta. Evidence against a mechanistically relevant association between enzyme and inhibitor.
abstract: Five proteins from human placenta capable of inhibiting pancreatic phospholipase A2 were purified. Two of these proteins were identified as lipocortins I and II. The other three proteins were immunologically distinct from lipocortins I and II and had apparent subunit molecular masses of 32, 33, and 73 kDa as estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Amino acid sequence analysis of peptides produced by cyanogen bromide digestion indicated sequence homology of these proteins with lipocortin I and the heavy chain subunit of lipocortin II. Two of these proteins were identified as endonexin II and 67-kDa calelectrin. The third protein appears to be the human form of bovine endonexin I, also characterized as porcine protein II. Sedimentation equilibrium analysis of lipocortin I, endonexin I and II, and the 67-kDa calelectrin suggested monomer-dimer equilibria with dissociation constants in the range of 0.33-1.3 X 10(-3) M and monomer molecular masses of 38,050, 36,400, 36,850, and 73,610 Da, respectively. Self-association of lipocortin II was described by dimerization of a protomer (K12 = 5.3 x 10(-7) M), followed by an indefinite self-association of the dimer (isodesmic dissociation constant, Kiso = 3.6 x 10(-6) M). The protomer molecular mass was 48,800 Da, consistent with a heterodimeric structure composed of one heavy (38,600 Da) and one light (10,944 Da) chain as previously characterized for lipocortin II. Sedimentation equilibrium analysis of mixtures of individual protein inhibitors and purified pancreatic phospholipase A2 indicated weak association between enzyme and inhibitor (Kd greater than or equal to 3 x 10(-5) M), insufficient to account for the observed inhibition of enzyme activity.
authors.affiliation: Department of Medicine, University of Washington, Seattle 98195.
authors.forename: N G
authors.initials: NG
authors.lastname: Ahn
authors.forename: D C
authors.initials: DC
authors.lastname: Teller
authors.forename: M J
authors.initials: MJ
authors.lastname: Bienkowski
authors.forename: B A
authors.initials: BA
authors.lastname: McMullen
authors.forename: E W
authors.initials: EW
authors.lastname: Lipkin
authors.forename: C
authors.initials: C
authors.lastname: de Haën
mesh_terms: D017304:Annexin A5; D017302:Annexins; D002135:Calcium-Binding Proteins / Q000494:pharmacology; D006023:Glycoproteins / Q000494:pharmacology*; D006801:Humans; D008970:Molecular Weight; D010740:Phospholipases / Q000037:antagonists & inhibitors*; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D010920:Placenta / Q000201:enzymology*; D014461:Ultracentrifugation
chemical_list: D017304:Annexin A5; D017302:Annexins; D002135:Calcium-Binding Proteins; D006023:Glycoproteins; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2